Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine

Immunoproteomics and Immunoinformatics Analysis of Cryptococcus Gattii : Novel Candidate Antigens for Diagnosis

“…The proteins recognized in vitro by antibodies in this work probably have the same antigenic determinants that induce antibodies in vivo. This approach has frequently been used to identify immunogenic proteins and, consequently, new targets to diagnose several diseases [41][42][43][44][45][46][47][48][49][50][51][52][53][54]. Although similar results have been achieved in cryptococcosis using murine [55] and koala models [56], this is the first report in human beings.…”

Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

“…Thirty days after challenge, mice were sacrificed and their spleens removed. Each spleen was homogenized in 1 ml 0.9% NaCl containing 0.1% Triton X-100, serially diluted and plated on Brucella agar in triplicates and incubated at 37 • C for 3-4 days [41]. Number of colonies was expressed as the mean log CFU ± SD per group.…”

Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis

“…Despite the role that Th1 and CD8 + T cell responses play in protection against brucellosis, the majority of Brucella spp. subunit immunization studies have and continue to primarily use Alum (aluminum salts) or Freund's adjuvant (FA) in immunization formulations (Pasquevich et al, 2009, 2011; Lowry et al, 2011; Yang et al, 2011a,b; Fu et al, 2012; Goel and Bhatnagar, 2012; Jain et al, 2012; Li et al, 2012). This practice is inconsistent with the protective mechanisms against brucellosis since Alum is primarily associated with a Th2 response, FA elicits a mixed Th1/Th2 response and both have no demonstrated ability to stimulate of CD8 + T cell responses (Coffman et al, 2010); however, the use of Alum may be associated with its acceptance for use in human subjects.…”